Answers are grounded in this paper and cite their sources.
Cohort study reveals limited long-term pain relief following sixty-day temporary peripheral nerve stimulation in chronic pain, indicating that sustained post-explant response is uncommon.
Objective: To prospectively evaluate pain relief and functional outcomes through 14 months after 60-day percutaneous peripheral nerve stimulation (PNS) in a consecutive real-world cohort. Design: Prospective single-center observational cohort study of 102 consecutive patients implanted with 60-day temporary percutaneous PNS for chronic pain. Outcomes were collected at 2 weeks and 2, 5, 8, 11, and 14 months. The principal outcome measure was the proportion reporting ≥50% pain relief at each follow-up interval. Secondary outcomes included ≥80% pain relief, numeric pain rating scale (NRS), Brief Pain Inventory item 9a (BP-9a), Oswestry Disability Index, Patient Global Impression of Change (PGIC), and adverse events. Results: ≥50% pain relief was reported by 49/102 (48.0%; 95% CI, 38.0–58.2%) at 2 weeks, 34/102 (33.3%; 95% CI, 24.3–43.4%) at 2 months, 16/102 (15.7%; 95% CI, 9.2–24.2%) at 5 months, 10/102 (9.8%; 95% CI, 4.8–17.3%) at 8 months, and 4/102 (3.9%; 95% CI, 1.1–9.7%) at 11 months. At 14 months, no participants met the ≥50% threshold (0/4 observed case; 0/102 under the fixed-denominator framework). Conclusions: In this heterogeneous real-world cohort, 60-day temporary PNS produced short-term benefit in a subset of patients, but durable post-explant response was uncommon.
No takes yet. Share an insight, caveat, or question.
Sherwood et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: